NCT06271928 is a EARLY_PHASE1 clinical trial of Yijing Keli in Ovarian Aging, sponsored by Tongji Hospital.

Who is sponsoring NCT06271928?

NCT06271928 is sponsored by Tongji Hospital.

What drugs are being tested in NCT06271928?

Interventions in NCT06271928: Yijing Keli.

What condition does NCT06271928 study?

NCT06271928 studies Ovarian Aging.

Is NCT06271928 still recruiting?

NCT06271928 is currently status unknown. Last updated 22 February 2024.

Last reviewed 2024-02-22 · How we verify

NCT06271928

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Clinical Study of Yijing Keli in the Treatment of Ovarian Aging

Status unknown EARLY_PHASE1 Last updated 22 February 2024

What this trial tests

EARLY_PHASE1 trial testing Yijing Keli in Ovarian Aging in 100 participants. Status unknown.

Timeline

1 October 2021

Primary endpoint
1 January 2024

1 January 2025

Quick facts

Lead sponsor	Tongji Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 October 2021
Primary completion	1 January 2024
Estimated completion	1 January 2025
Sites	1 location across China

Drugs / interventions tested

Yijing Keli — full drug profile →

Conditions studied

Ovarian Aging — all drugs for Ovarian Aging →

Sponsor

Tongji Hospital

Who can join

Adults 18 to 55, female only, with Ovarian Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ovarian aging (OA) seriously affects the physical and mental health of women. Nowadays, Chinese herbs have huge appeal and potential in treating OA. We have created a new Chinese herbal combination Yijing Keli, whereas its safety and efficacy still need to be validated. Hence, we will perform a population-based, multicenter study to confirm the safety and efficacy of Yijing Keli in therapy of OA. We aim to provide a solid evidence for TCM in therapy of OA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ovarian Aging

Currently open trials in the same condition.

NCT06831019 — The ROAR Study: Reactive Oxygen Species and Reproduction · recruiting

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06271928 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 22 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06271928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing